Zacks Investment Research on MSN7h
AXSM Settles Sunosi Patent Litigation With Hikma PharmaceuticalsAxsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to ...
In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a price ...
Zacks Investment Research on MSN2d
AXSM Gets Positive FDA Feedback for Alzheimer's Agitation Drug FilingAxsome Therapeutics AXSM announced that it has received formal feedback from the FDA on its plans to seek approval for AXS-05 ...
15h
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has earned a consensus rating of “Buy” from the fifteen ratings ...
Axsome Therapeutics (AXSM) announced that it has entered into a settlement agreement with Hikma Pharmaceuticals (HKMPF), resolving patent ...
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective hoisted by stock analysts at Robert W. Baird from ...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced that the EMERGE Phase 3 trial of Symbravo (MoSEIC meloxicam and rizatriptan ...
Axsome Therapeutics (AXSM) is climbing nearly 4% after Swiss bank UBS increased its price target on the shares to $133 from $105. The bank is confident that the company's potential treatment for ...
AXSOME THERAPEUTICS ($AXSM) posted quarterly earnings results on Tuesday, February 18th. The company reported earnings of -$0.96 per share, beating estimates of -$1. ...
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback